G Medical Updates On Patient Enrollment Growth For Its Home Monitoring Services Of 194% From January Through April 2023, As Compared To The Same Period In 2022
G Medical Updates On Patient Enrollment Growth For Its Home Monitoring Services Of 194% From January Through April 2023, As Compared To The Same Period In 2022
G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company" or "G Medical"), a global leader in next-generation mobile health (mHealth) and digital health, is excited to report that patient enrollment has grown in its home monitoring services by 194% between January and April of 2023, as compared to the same period last year. The increase is due to growing demand for homecare monitoring. As previously announced, in the first quarter of 2023, G Medical signed an agreement with AdventHealth of Central Florida ("AdventHealth"), an operator of 20 hospitals and emergency rooms. AdventHealth experiences on average 5.7 million patient visits per year. G Medical also recently signed an agreement with MiCare Path to integrate MiCare Path's software platform and visualization tools to its devices. By integrating MiCare Path's virtual health solutions with G Medical's global health solutions and devices, physicians and patients will benefit from the next-generation care driving better outcomes for patients across all services. The G Medical collaboration will allow for a total remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) solution from service to exceptional future solutions. The Company looks forward to announcing additional key agreements in 2023.
下一代移动健康（mHealth）和数字医疗领域的全球领导者G Medical Innovations Holdings Ltd.（纳斯达克股票代码：GMVD）（“公司” 或 “G Medical”）兴奋地报告，与去年同期相比，其家庭监测服务的患者注册人数增长了194％。这一增长是由于对家庭护理监测的需求不断增长。正如先前宣布的那样，在2023年第一季度，G Medical与拥有20家医院和急诊室的运营商佛罗里达州中部的AdventHealth（“AdventHealth”）签署了一项协议。AdventHealth平均每年接待570万名患者。G Medical 最近还与 MiCare Path 签署了一项协议，将 miCare Path 的软件平台和可视化工具集成到其设备中。 通过将MiCare Path的虚拟健康解决方案与G Medical的全球健康解决方案和设备相结合，医生和患者将受益于下一代护理，从而在所有服务中为患者带来更好的疗效。G Medical的合作将实现从服务到卓越的未来解决方案的全面远程患者监测（RPM）和远程治疗监测（RTM）解决方案。公司期待在2023年宣布更多关键协议。
In line with its strategy of providing remote health services, in the second half of 2022, G Medical entered the at home laboratory testing market by developing 31 test kits for use by consumers at its CLIA-certified laboratory in Austin, Texas, which is now fully operational. G Medical expects that in the third quarter of 2023 consumers will be able to purchase these kits at retail stores or via online purchase. From the comfort and privacy of their own home, consumers will be able to use its kits to collect their own saliva, urine or blood sample and send it by mail to its lab in Austin for testing and analysis and receive complete report within 48 hours.
根据其提供远程医疗服务的战略，G Medical在2022年下半年进入了家庭实验室测试市场，开发了31套检测试剂盒，供消费者在其位于德克萨斯州奥斯汀的CLIA认证实验室使用，该实验室现已全面投入运营。G Medical预计，在2023年第三季度，消费者将能够在零售商店或通过在线购买购买这些试剂盒。消费者可以在家中舒适和私密地使用其试剂盒收集自己的唾液、尿液或血液样本，然后将其邮寄到奥斯汀的实验室进行测试和分析，并在48小时内收到完整的报告。
译文内容由第三方软件翻译。